Biography

Professor Kiernan is a graduate of University College Dublin (M.B. B.Ch. B.A.O. 1999). He completed his medical residency and early cardiology training in Ireland and the USA. He was awarded his MD Thesis (Cellular therapies for Cardiovascular Disease) from Mayo Clinic, Minnesota USA. He then pursued a fellowship in Interventional and Structural Cardiology in Massachusetts General Hospital/Harvard Medical School, Boston USA (2007-2009). He took up post of Consultant Cardiologist in Cork University Hospital, 2009 and moved to University Hospital Limerick 2012 where he was promoted to Clinical Lead for Cardiology, UL Hospitals Group and Associate Professor of Medicine Graduate Entry Medical School, University of Limerick. Since in post, he has spearheaded the introduction of 24/7 ST-Elevation Myocardial Infarction (STEMI) service for the region as well as multi-disciplinary heart team meetings, structural heart disease programme for the region and development of a cardiology research team which partake in both national and international clinical trials and research projects.

TRAINING:

Professor Tom Kiernan is a Consultant Interventional Cardiologist and the Clinical Director at Beacon Limerick. Prof Kiernan is a graduate of University College Dublin. He completed his medical residency and early cardiology training in Ireland and the USA. He completed interventional cardiology research and clinical interventional fellowship at Mayo Clinic, Rochester, Minnesota and Massachusetts General Hospital/Harvard Medical School.

EXPERIENCE:

Professor Kiernan was appointed Academic Lead for Cardiology, UL Hospitals Group and Associate Professor of Medicine Graduate Entry Medical School, University of Limerick in 2012. Since in post, he has spearheaded the introduction of a 24/7 ST-Elevation Myocardial Infarction (STEMI) service for the region. He currently serves as the National Lead for PCI as part of the Clinical Advisory Group and as Council Member of the Irish Cardiac Society.

Peer Reviewed Journals

2021

Interhospital and interindividual variability in secondary prevention: a comparison of outpatients with a history of chronic coronary syndrome versus outpatients with a history of acute coronary syndrome (the iASPIRE Study)

Curneen, JMG;Judge, C;Traynor, B;Buckley, A;Saiva, L;Murphy, L;Murray, D;Fleming, S;Kearney, P;Murphy, RT;Aleong, G;Kiernan, TJ;O'Neill, J;Moore, D;Nicaodhabhui, B;Birrane, J;Hall, P;Crowley, J;Gibson, I;Jennings, CS;Wood, D;Kotseva, K;McEvoy, JW (2021) Interhospital and interindividual variability in secondary prevention: a comparison of outpatients with a history of chronic coronary syndrome versus outpatients with a history of acute coronary syndrome (the iASPIRE Study). LONDON : BMJ PUBLISHING GROUP Open Heart

Books

This author has not written any publications of this type yet.

Book Chapters

This author has not written any publications of this type yet.

Edited Books

This author has not written any publications of this type yet.

Other Journals

This author has not written any publications of this type yet.

Conference Publications

This author has not written any publications of this type yet.

Conference Contributions

This author has not written any publications of this type yet.

Published Reports

This author has not written any publications of this type yet.

Editorials

This author has not written any publications of this type yet.

Book Reviews

This author has not written any publications of this type yet.

Other Publications

2021

Diagnosing, fast and slow

Coughlan, JJ;Mullins, CF;Kiernan, TJ (2021) Diagnosing, fast and slow. LONDON : BMJ PUBLISHING GROUP Postgraduate medical journal :103-109

2017

The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban)

O'connor, CT;Kiernan, TJ;Yan, BP (2017) The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). ABINGDON : TAYLOR & FRANCIS LTD EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY :725-739